You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameItraconazole
Accession NumberDB01167  (APRD00040)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionOne of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis. [PubChem]
Structure
Thumb
Synonyms
Itraconazol
Itraconazole
Itraconazolum
Itrizole (tn)
Oriconazole
Sporanox (tn)
External Identifiers
  • R51211
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Itraconazolecapsule100 mg/1oralPatriot Pharmaceuticals2005-02-01Not applicableUs
Itraconazolecapsule100 mg/1oralCarilion Materials Management2005-02-01Not applicableUs
Onmeltablet200 mg/1oralMerz Pharmaceuticals, LLC2012-11-01Not applicableUs
Sporanoxcapsule100 mg/1oralbryant ranch prepack1992-09-11Not applicableUs
Sporanoxcapsule100 mg/1oralJanssen Pharmaceuticals, Inc.1992-09-11Not applicableUs
Sporanoxcapsule100 mgoralJanssen Inc1993-12-31Not applicableCanada
Sporanoxsolution10 mg/mLoralJanssen Pharmaceuticals, Inc.1997-02-21Not applicableUs
Sporanox Oral Solution 10mg/mlsolution10 mgoralJanssen Inc1997-07-28Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Itraconazolecapsule100 mg/1oralEon Labs, Inc.2004-05-28Not applicableUs
Itraconazolecapsule100 mg/1oralMylan Pharmaceuticals Inc.2012-07-20Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ItrizoleNot Available
OriconazoleNot Available
SporalNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII304NUG5GF4
CAS number84625-61-6
WeightAverage: 705.633
Monoisotopic: 704.239307158
Chemical FormulaC35H38Cl2N8O4
InChI KeyInChIKey=VHVPQPYKVGDNFY-ZPGVKDDISA-N
InChI
InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1
IUPAC Name
1-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one
SMILES
CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[[email protected]]2CO[C@@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentPhenylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Phenylpiperazine
  • Phenyl-1,3,4-triazole
  • Phenyl-1,2,4-triazole
  • Phenyltriazole
  • Substituted aniline
  • Dialkylarylamine
  • Phenol ether
  • 1,3-dichlorobenzene
  • Glycerol ether
  • Halobenzene
  • Chlorobenzene
  • Aniline
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • 1,2,4-triazole
  • Triazole
  • Azole
  • Meta-dioxolane
  • Tertiary amine
  • Oxacycle
  • Azacycle
  • Ether
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
PharmacodynamicsItraconazole is an imidazole/triazole type antifungal agent. Itraconazole is a highly selective inhibitor of fungal cytochrome P-450 sterol C-14 α-demethylation via the inhibition of the enzyme cytochrome P450 14α-demethylase. This enzyme converts lanosterol to ergosterol, and is required in fungal cell wall synthesis. The subsequent loss of normal sterols correlates with the accumulation of 14 α-methyl sterols in fungi and may be partly responsible for the fungistatic activity of fluconazole. Mammalian cell demethylation is much less sensitive to fluconazole inhibition. Itraconazole exhibits in vitro activity against Cryptococcus neoformans and Candida spp. Fungistatic activity has also been demonstrated in normal and immunocompromised animal models for systemic and intracranial fungal infections due to Cryptococcus neoformans and for systemic infections due to Candida albicans.
Mechanism of actionItraconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Itraconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.
Related Articles
AbsorptionThe absolute oral bioavailability of itraconazole is 55%, and is maximal when taken with a full meal.
Volume of distribution
  • 796 ± 185 L
Protein binding99.8%
Metabolism

Itraconazole is extensively metabolized by the liver into a large number of metabolites, including hydroxyitraconazole, the major metabolite. The main metabolic pathways are oxidative scission of the dioxolane ring, aliphatic oxidation at the 1-methylpropyl substituent, N-dealkylation of this 1-methylpropyl substituent, oxidative degradation of the piperazine ring and triazolone scission.

SubstrateEnzymesProduct
Itraconazole
hydroxyitraconazoleDetails
Route of eliminationItraconazole is metabolized predominately by the cytochrome P450 3A4 isoenzyme system (CYP3A4) in the liver, resulting in the formation of several metabolites, including hydroxyitraconazole, the major metabolite. Fecal excretion of the parent drug varies between 3-18% of the dose. Renal excretion of the parent drug is less than 0.03% of the dose. About 40% of the dose is excreted as inactive metabolites in the urine. No single excreted metabolite represents more than 5% of a dose.
Half life21 hours
Clearance
  • 381 +/- 95 mL/minute [IV administration]
ToxicityNo significant lethality was observed when itraconazole was administered orally to mice and rats at dosage levels of 320 mg/kg or to dogs at 200 mg/kg.
Affected organisms
  • Fungi, yeast and protozoans
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9973
Blood Brain Barrier-0.6151
Caco-2 permeable+0.5511
P-glycoprotein substrateSubstrate0.6397
P-glycoprotein inhibitor IInhibitor0.7973
P-glycoprotein inhibitor IINon-inhibitor0.88
Renal organic cation transporterNon-inhibitor0.7497
CYP450 2C9 substrateNon-substrate0.8116
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateNon-inhibitor0.7666
CYP450 2C9 inhibitorInhibitor0.618
CYP450 2D6 inhibitorNon-inhibitor0.8622
CYP450 2C19 inhibitorInhibitor0.5703
CYP450 3A4 inhibitorInhibitor0.5279
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8219
Ames testAMES toxic0.5303
CarcinogenicityNon-carcinogens0.7478
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.3118 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5782
hERG inhibition (predictor II)Inhibitor0.6096
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsuleoral100 mg/1
Tabletoral200 mg/1
Capsuleoral100 mg
Solutionoral10 mg/mL
Solutionoral10 mg
Prices
Unit descriptionCostUnit
Itraconazole 28 100 mg capsule Disp Pack270.89USD disp
Itraconazole powder32.13USD g
Sporanox 100 mg capsule12.14USD capsule
Itraconazole 100 mg capsule9.46USD capsule
Sporanox 10 mg/ml Solution1.41USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1336498 No1995-08-012012-08-01Canada
CA2142848 No1999-11-162013-08-27Canada
US5633015 No1994-05-272014-05-27Us
US6407079 No1999-06-182019-06-18Us
US6509038 No1997-05-122017-05-12Us
US7081255 No1997-05-122017-05-12Us
US8486456 No2008-10-032028-10-03Us
US8591948 No1997-05-122017-05-12Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point166.2 °CNot Available
water solubilityInsolubleNot Available
logP5.66HTTP://WWW.RXLIST.COM
pKa3.70Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00964 mg/mLALOGPS
logP5.48ALOGPS
logP7.31ChemAxon
logS-4.9ALOGPS
pKa (Strongest Basic)3.92ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area100.79 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity200.4 m3·mol-1ChemAxon
Polarizability74.7 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Jong-Soo Woo, Hong-Gi Yi, “Antifungal oral composition containing itraconazole and process for preparing same.” U.S. Patent US6039981, issued May, 1998.

US6039981
General ReferencesNot Available
External Links
ATC CodesJ02AC02
AHFS Codes
  • 08:14.08
PDB Entries
FDA labelDownload (1.58 MB)
MSDSDownload (73.6 KB)
Interactions
Drug Interactions
Drug
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Itraconazole.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Itraconazole.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Itraconazole.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Itraconazole.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Itraconazole.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Itraconazole.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Itraconazole.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Itraconazole.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Itraconazole.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Itraconazole.
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Itraconazole.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Itraconazole.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Itraconazole.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Itraconazole.
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Itraconazole.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Itraconazole.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Itraconazole.
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Itraconazole.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Itraconazole.
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Itraconazole.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Itraconazole.
Aluminum hydroxideThe serum concentration of Itraconazole can be decreased when it is combined with Aluminum hydroxide.
Aluminum phosphateThe serum concentration of Itraconazole can be decreased when it is combined with Aluminum phosphate.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Itraconazole.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Itraconazole.
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Itraconazole.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Itraconazole.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Itraconazole.
AmiodaroneThe metabolism of Itraconazole can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Itraconazole.
AmlodipineThe risk or severity of adverse effects can be increased when Itraconazole is combined with Amlodipine.
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Itraconazole.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Itraconazole.
AmrinoneThe risk or severity of adverse effects can be increased when Itraconazole is combined with Amrinone.
AnagrelideItraconazole may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Itraconazole.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Itraconazole.
ApremilastThe metabolism of Apremilast can be decreased when combined with Itraconazole.
AprepitantThe serum concentration of Itraconazole can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Itraconazole.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Itraconazole.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Itraconazole.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Itraconazole.
ArtemetherThe metabolism of Artemether can be decreased when combined with Itraconazole.
AsenapineThe serum concentration of Itraconazole can be decreased when it is combined with Asenapine.
AsenapineThe metabolism of Asenapine can be decreased when combined with Itraconazole.
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Itraconazole.
AtazanavirThe metabolism of Itraconazole can be decreased when combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Itraconazole.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Itraconazole.
AtomoxetineThe metabolism of Itraconazole can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Itraconazole.
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Itraconazole.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Itraconazole.
AzelastineThe metabolism of Azelastine can be decreased when combined with Itraconazole.
AzelnidipineThe risk or severity of adverse effects can be increased when Itraconazole is combined with Azelnidipine.
AzimilideThe risk or severity of adverse effects can be increased when Itraconazole is combined with Azimilide.
AzithromycinItraconazole may increase the QTc-prolonging activities of Azithromycin.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Itraconazole.
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Itraconazole.
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Itraconazole.
BedaquilineItraconazole may increase the QTc-prolonging activities of Bedaquiline.
BenidipineThe risk or severity of adverse effects can be increased when Itraconazole is combined with Benidipine.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Itraconazole.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Itraconazole.
BepridilThe risk or severity of adverse effects can be increased when Itraconazole is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Itraconazole.
BexaroteneThe serum concentration of Itraconazole can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Itraconazole.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Itraconazole.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Itraconazole.
Bismuth SubcitrateThe serum concentration of Itraconazole can be decreased when it is combined with Bismuth Subcitrate.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Itraconazole.
BoceprevirThe metabolism of Itraconazole can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Itraconazole.
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Itraconazole.
BortezomibThe metabolism of Itraconazole can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Itraconazole can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Itraconazole.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Itraconazole.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Itraconazole.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Itraconazole.
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Itraconazole.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Itraconazole.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Itraconazole.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Itraconazole.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Itraconazole.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Itraconazole.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Itraconazole.
BupropionThe metabolism of Bupropion can be decreased when combined with Itraconazole.
BuspironeThe metabolism of Buspirone can be decreased when combined with Itraconazole.
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Itraconazole.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Itraconazole.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Itraconazole.
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Itraconazole.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Itraconazole.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Itraconazole.
Calcium carbonateThe serum concentration of Itraconazole can be decreased when it is combined with Calcium carbonate.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Itraconazole.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Itraconazole.
CarbamazepineThe serum concentration of Itraconazole can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Itraconazole.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Itraconazole.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Itraconazole.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Itraconazole.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Itraconazole.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Itraconazole.
CeliprololThe metabolism of Celiprolol can be decreased when combined with Itraconazole.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Itraconazole.
CeritinibThe serum concentration of Itraconazole can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Itraconazole.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Itraconazole.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Itraconazole.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Itraconazole.
ChloroquineItraconazole may increase the QTc-prolonging activities of Chloroquine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Itraconazole.
ChlorpromazineItraconazole may increase the QTc-prolonging activities of Chlorpromazine.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Itraconazole.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Itraconazole.
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Itraconazole.
CilnidipineThe risk or severity of adverse effects can be increased when Itraconazole is combined with Cilnidipine.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Itraconazole.
CimetidineThe serum concentration of Itraconazole can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Itraconazole.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Itraconazole.
CinnarizineThe risk or severity of adverse effects can be increased when Itraconazole is combined with Cinnarizine.
CiprofloxacinItraconazole may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Itraconazole.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Itraconazole.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Itraconazole.
ClarithromycinItraconazole may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe metabolism of Itraconazole can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Itraconazole can be decreased when combined with Clemastine.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Itraconazole.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Itraconazole.
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Itraconazole.
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Itraconazole.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Itraconazole.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Itraconazole.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Itraconazole.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Itraconazole.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Itraconazole.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Itraconazole.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Itraconazole.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Itraconazole.
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Itraconazole.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Itraconazole.
ClotrimazoleThe metabolism of Itraconazole can be decreased when combined with Clotrimazole.
ClozapineItraconazole may increase the QTc-prolonging activities of Clozapine.
CobicistatThe serum concentration of Cobicistat can be increased when it is combined with Itraconazole.
CobicistatThe metabolism of Itraconazole can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Itraconazole.
CocaineThe metabolism of Cocaine can be decreased when combined with Itraconazole.
CodeineThe metabolism of Codeine can be decreased when combined with Itraconazole.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Itraconazole.
ConivaptanThe serum concentration of Itraconazole can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Itraconazole.
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Itraconazole.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Itraconazole.
CrizotinibThe metabolism of Itraconazole can be decreased when combined with Crizotinib.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Itraconazole.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Itraconazole.
CyclosporineThe metabolism of Itraconazole can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Itraconazole.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Itraconazole.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Itraconazole.
DabrafenibThe serum concentration of Itraconazole can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Itraconazole.
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Itraconazole.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Itraconazole.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Itraconazole.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Itraconazole.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Itraconazole.
DapsoneThe metabolism of Dapsone can be decreased when combined with Itraconazole.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Itraconazole.
DarodipineThe risk or severity of adverse effects can be increased when Itraconazole is combined with Darodipine.
DarunavirThe serum concentration of Itraconazole can be increased when it is combined with Darunavir.
DarunavirThe metabolism of Darunavir can be decreased when combined with Itraconazole.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Itraconazole.
DasatinibThe serum concentration of Itraconazole can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Itraconazole.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Itraconazole.
DeferasiroxThe serum concentration of Itraconazole can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be increased when it is combined with Itraconazole.
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Itraconazole.
DelavirdineThe metabolism of Itraconazole can be decreased when combined with Delavirdine.
DeslanosideThe serum concentration of Deslanoside can be increased when it is combined with Itraconazole.
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Itraconazole.
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Itraconazole.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Itraconazole.
DexamethasoneThe serum concentration of Itraconazole can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Itraconazole.
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Itraconazole.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Itraconazole.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Itraconazole.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Itraconazole.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Itraconazole.
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Itraconazole.
DidanosineDidanosine can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
DienogestThe serum concentration of Dienogest can be increased when it is combined with Itraconazole.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Itraconazole.
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Itraconazole.
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Itraconazole.
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Itraconazole.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Itraconazole.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Itraconazole.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Itraconazole.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Itraconazole.
DihydroergotamineThe metabolism of Itraconazole can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Itraconazole.
DiltiazemThe metabolism of Itraconazole can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Itraconazole.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Itraconazole.
DisopyramideThe serum concentration of Disopyramide can be increased when it is combined with Itraconazole.
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Itraconazole.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Itraconazole.
DofetilideThe metabolism of Dofetilide can be decreased when combined with Itraconazole.
DolasetronItraconazole may increase the QTc-prolonging activities of Dolasetron.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Itraconazole.
DonepezilThe metabolism of Donepezil can be decreased when combined with Itraconazole.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Itraconazole.
DotarizineThe risk or severity of adverse effects can be increased when Itraconazole is combined with Dotarizine.
DoxepinThe serum concentration of Itraconazole can be decreased when it is combined with Doxepin.
DoxepinThe metabolism of Doxepin can be decreased when combined with Itraconazole.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Itraconazole.
DoxycyclineThe metabolism of Itraconazole can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Itraconazole.
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Itraconazole.
DronedaroneThe metabolism of Itraconazole can be decreased when combined with Dronedarone.
DroperidolItraconazole may increase the QTc-prolonging activities of Droperidol.
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Itraconazole.
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Itraconazole.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Itraconazole.
EfavirenzThe serum concentration of Itraconazole can be decreased when it is combined with Efavirenz.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Itraconazole.
EfonidipineThe risk or severity of adverse effects can be increased when Itraconazole is combined with Efonidipine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Itraconazole.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Itraconazole.
ElvitegravirThe serum concentration of Elvitegravir can be increased when it is combined with Itraconazole.
EnalaprilThe metabolism of Enalapril can be decreased when combined with Itraconazole.
EnzalutamideThe serum concentration of Itraconazole can be decreased when it is combined with Enzalutamide.
EnzalutamideThe serum concentration of Enzalutamide can be increased when it is combined with Itraconazole.
EperisoneThe risk or severity of adverse effects can be increased when Itraconazole is combined with Eperisone.
EpinastineThe serum concentration of Itraconazole can be decreased when it is combined with Epinastine.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Itraconazole.
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Itraconazole.
EquileninThe serum concentration of Equilenin can be increased when it is combined with Itraconazole.
EquilinThe serum concentration of Equilin can be increased when it is combined with Itraconazole.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Itraconazole.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Itraconazole.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Itraconazole.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Itraconazole.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Itraconazole.
ErythromycinItraconazole may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Itraconazole can be decreased when combined with Erythromycin.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Itraconazole.
Eslicarbazepine acetateThe serum concentration of Itraconazole can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe serum concentration of Itraconazole can be decreased when it is combined with Esomeprazole.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Itraconazole.
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Itraconazole.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Itraconazole.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Itraconazole.
EstramustineThe metabolism of Estramustine can be decreased when combined with Itraconazole.
EstriolThe serum concentration of Estriol can be increased when it is combined with Itraconazole.
EstroneThe serum concentration of Estrone can be increased when it is combined with Itraconazole.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Itraconazole.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Itraconazole.
EthanolThe metabolism of Ethanol can be decreased when combined with Itraconazole.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Itraconazole.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Itraconazole.
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Itraconazole.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Itraconazole.
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Itraconazole.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Itraconazole.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Itraconazole.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Itraconazole.
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Itraconazole.
EtravirineThe serum concentration of Itraconazole can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Itraconazole.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Itraconazole.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Itraconazole.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Itraconazole.
FamotidineThe serum concentration of Itraconazole can be decreased when it is combined with Famotidine.
FelbamateThe metabolism of Felbamate can be decreased when combined with Itraconazole.
FelodipineThe serum concentration of Felodipine can be increased when it is combined with Itraconazole.
FendilineThe risk or severity of adverse effects can be increased when Itraconazole is combined with Fendiline.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Itraconazole.
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Itraconazole.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Itraconazole.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Itraconazole.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Itraconazole.
FinasterideThe metabolism of Finasteride can be decreased when combined with Itraconazole.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Itraconazole.
FlecainideItraconazole may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Itraconazole.
FluconazoleThe metabolism of Itraconazole can be decreased when combined with Fluconazole.
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Itraconazole.
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Itraconazole.
FlunarizineThe risk or severity of adverse effects can be increased when Itraconazole is combined with Flunarizine.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Itraconazole.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Itraconazole.
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Itraconazole.
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Itraconazole.
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Itraconazole.
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Itraconazole.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Itraconazole.
FlupentixolItraconazole may increase the QTc-prolonging activities of Flupentixol.
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Itraconazole.
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Itraconazole.
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Itraconazole.
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Itraconazole.
FlutamideThe metabolism of Flutamide can be decreased when combined with Itraconazole.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Itraconazole.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Itraconazole.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Itraconazole.
FluvoxamineThe metabolism of Itraconazole can be decreased when combined with Fluvoxamine.
FosamprenavirThe serum concentration of the active metabolites of Fosamprenavir can be increased when Fosamprenavir is used in combination with Itraconazole.
FosamprenavirThe metabolism of Itraconazole can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Itraconazole can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Itraconazole can be decreased when it is combined with Fosphenytoin.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Itraconazole.
Fusidic AcidThe serum concentration of Itraconazole can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Itraconazole is combined with Gabapentin.
Gadobenic acidItraconazole may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Itraconazole.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Itraconazole.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Itraconazole.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Itraconazole.
GemifloxacinItraconazole may increase the QTc-prolonging activities of Gemifloxacin.
GlipizideThe metabolism of Glipizide can be decreased when combined with Itraconazole.
GlyburideThe metabolism of Glyburide can be decreased when combined with Itraconazole.
GoserelinItraconazole may increase the QTc-prolonging activities of Goserelin.
GranisetronItraconazole may increase the QTc-prolonging activities of Granisetron.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Itraconazole.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Itraconazole.
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Itraconazole.
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Itraconazole.
HaloperidolItraconazole may increase the QTc-prolonging activities of Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Itraconazole.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Itraconazole.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Itraconazole.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Itraconazole.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Itraconazole.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Itraconazole.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Itraconazole.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Itraconazole.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Itraconazole.
IbutilideItraconazole may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Itraconazole can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Itraconazole resulting in a loss in efficacy.
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Itraconazole.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Itraconazole.
ImatinibThe metabolism of Itraconazole can be decreased when combined with Imatinib.
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Itraconazole.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Itraconazole.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Itraconazole.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Itraconazole.
IndapamideThe metabolism of Indapamide can be decreased when combined with Itraconazole.
IndinavirThe metabolism of Itraconazole can be decreased when combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Itraconazole.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Itraconazole.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Itraconazole.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Itraconazole.
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Itraconazole.
IsavuconazoniumThe metabolism of Itraconazole can be decreased when combined with Isavuconazonium.
IsoniazidThe serum concentration of Itraconazole can be decreased when it is combined with Isoniazid.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Itraconazole.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Itraconazole.
IsradipineThe risk or severity of adverse effects can be increased when Itraconazole is combined with Isradipine.
IsradipineThe metabolism of Itraconazole can be decreased when combined with Isradipine.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Itraconazole can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Itraconazole.
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Itraconazole.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Itraconazole.
KetamineThe metabolism of Ketamine can be decreased when combined with Itraconazole.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Itraconazole.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Itraconazole.
KetoconazoleThe metabolism of Itraconazole can be decreased when combined with Ketoconazole.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Itraconazole.
LacidipineThe risk or severity of adverse effects can be increased when Itraconazole is combined with Lacidipine.
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Itraconazole.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Itraconazole.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Itraconazole.
LansoprazoleThe serum concentration of Itraconazole can be decreased when it is combined with Lansoprazole.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Itraconazole.
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Itraconazole.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Itraconazole.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Itraconazole.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Itraconazole.
LenvatinibItraconazole may increase the QTc-prolonging activities of Lenvatinib.
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Itraconazole.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Itraconazole.
LeuprolideItraconazole may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Itraconazole.
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Itraconazole.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Itraconazole.
LevofloxacinItraconazole may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Itraconazole.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Itraconazole.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Itraconazole.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Itraconazole.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Itraconazole.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Itraconazole.
LisurideThe metabolism of Lisuride can be decreased when combined with Itraconazole.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Itraconazole.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Itraconazole.
LopinavirThe serum concentration of Itraconazole can be increased when it is combined with Lopinavir.
LopinavirThe metabolism of Lopinavir can be decreased when combined with Itraconazole.
LoratadineThe metabolism of Loratadine can be decreased when combined with Itraconazole.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Itraconazole.
LosartanThe metabolism of Losartan can be decreased when combined with Itraconazole.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Itraconazole.
LovastatinThe metabolism of Itraconazole can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Itraconazole can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Itraconazole can be decreased when it is combined with Lumacaftor.
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Itraconazole.
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Itraconazole.
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Itraconazole.
MagaldrateThe serum concentration of Itraconazole can be decreased when it is combined with Magaldrate.
Magnesium carbonateThe serum concentration of Itraconazole can be decreased when it is combined with Magnesium carbonate.
Magnesium hydroxideThe serum concentration of Itraconazole can be decreased when it is combined with Magnesium hydroxide.
Magnesium oxideThe serum concentration of Itraconazole can be decreased when it is combined with Magnesium oxide.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Itraconazole is combined with Magnesium Sulfate.
Magnesium TrisilicateThe serum concentration of Itraconazole can be decreased when it is combined with Magnesium Trisilicate.
ManidipineThe risk or severity of adverse effects can be increased when Itraconazole is combined with Manidipine.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Itraconazole.
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Itraconazole.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Itraconazole.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Itraconazole.
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Itraconazole.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Itraconazole.
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Itraconazole.
MeloxicamThe serum concentration of Meloxicam can be decreased when it is combined with Itraconazole.
MethadoneThe serum concentration of Methadone can be increased when it is combined with Itraconazole.
MethanthelineThe serum concentration of Itraconazole can be decreased when it is combined with Methantheline.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Itraconazole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Itraconazole.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Itraconazole.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Itraconazole.
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Itraconazole.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Itraconazole.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Itraconazole.
MetiamideThe serum concentration of Itraconazole can be decreased when it is combined with Metiamide.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Itraconazole.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Itraconazole.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Itraconazole.
MianserinThe metabolism of Mianserin can be decreased when combined with Itraconazole.
MibefradilThe risk or severity of adverse effects can be increased when Itraconazole is combined with Mibefradil.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Itraconazole.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Itraconazole.
MifepristoneThe serum concentration of Mifepristone can be increased when it is combined with Itraconazole.
MifepristoneThe metabolism of Itraconazole can be decreased when combined with Mifepristone.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Itraconazole.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Itraconazole.
MitotaneThe serum concentration of Itraconazole can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Itraconazole.
ModafinilThe serum concentration of Itraconazole can be decreased when it is combined with Modafinil.
ModafinilThe metabolism of Modafinil can be decreased when combined with Itraconazole.
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Itraconazole.
MontelukastThe metabolism of Montelukast can be decreased when combined with Itraconazole.
MorphineThe serum concentration of Morphine can be increased when it is combined with Itraconazole.
MoxifloxacinItraconazole may increase the QTc-prolonging activities of Moxifloxacin.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Itraconazole.
NadololThe serum concentration of Nadolol can be increased when it is combined with Itraconazole.
NafcillinThe serum concentration of Itraconazole can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Itraconazole.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Itraconazole.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Itraconazole.
NefazodoneThe metabolism of Itraconazole can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Itraconazole can be decreased when combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Itraconazole.
NetupitantThe serum concentration of Itraconazole can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Itraconazole can be decreased when it is combined with Nevirapine.
NevirapineThe metabolism of Nevirapine can be decreased when combined with Itraconazole.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Itraconazole.
NicotineThe metabolism of Nicotine can be decreased when combined with Itraconazole.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Itraconazole.
NiguldipineThe risk or severity of adverse effects can be increased when Itraconazole is combined with Niguldipine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Itraconazole.
NilotinibThe metabolism of Itraconazole can be decreased when combined with Nilotinib.
NiludipineThe risk or severity of adverse effects can be increased when Itraconazole is combined with Niludipine.
NilvadipineThe risk or severity of adverse effects can be increased when Itraconazole is combined with Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Itraconazole is combined with Nimesulide.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Itraconazole.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Itraconazole.
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Itraconazole.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Itraconazole.
NitrendipineThe risk or severity of adverse effects can be increased when Itraconazole is combined with Nitrendipine.
NizatidineThe serum concentration of Itraconazole can be decreased when it is combined with Nizatidine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Itraconazole.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Itraconazole.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Itraconazole.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Itraconazole.
OfloxacinItraconazole may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe serum concentration of Itraconazole can be decreased when it is combined with Olanzapine.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Itraconazole.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Itraconazole.
OlaparibThe metabolism of Itraconazole can be decreased when combined with Olaparib.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Itraconazole.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Itraconazole.
OmeprazoleThe serum concentration of Itraconazole can be decreased when it is combined with Omeprazole.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Itraconazole.
OndansetronItraconazole may increase the QTc-prolonging activities of Ondansetron.
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Itraconazole.
OsimertinibThe serum concentration of Itraconazole can be increased when it is combined with Osimertinib.
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Itraconazole.
OuabainThe serum concentration of Ouabain can be increased when it is combined with Itraconazole.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Itraconazole.
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Itraconazole.
OxycodoneThe risk or severity of adverse effects can be increased when Itraconazole is combined with Oxycodone.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Itraconazole.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Itraconazole.
PalbociclibThe serum concentration of Itraconazole can be increased when it is combined with Palbociclib.
PaliperidoneItraconazole may increase the QTc-prolonging activities of Paliperidone.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Itraconazole.
PanobinostatItraconazole may increase the QTc-prolonging activities of Panobinostat.
PantoprazoleThe serum concentration of Itraconazole can be decreased when it is combined with Pantoprazole.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Itraconazole.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Itraconazole.
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Itraconazole.
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Itraconazole.
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Itraconazole.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Itraconazole.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Itraconazole.
PentamidineItraconazole may increase the QTc-prolonging activities of Pentamidine.
PentobarbitalThe serum concentration of Itraconazole can be decreased when it is combined with Pentobarbital.
PerampanelThe metabolism of Perampanel can be decreased when combined with Itraconazole.
PerflutrenItraconazole may increase the QTc-prolonging activities of Perflutren.
PergolideThe metabolism of Pergolide can be decreased when combined with Itraconazole.
PerhexilineThe risk or severity of adverse effects can be increased when Itraconazole is combined with Perhexiline.
PermethrinThe metabolism of Permethrin can be decreased when combined with Itraconazole.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Itraconazole.
PethidineThe metabolism of Pethidine can be decreased when combined with Itraconazole.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Itraconazole.
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Itraconazole.
PhenobarbitalThe serum concentration of Itraconazole can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Itraconazole.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Itraconazole.
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Itraconazole.
PhenytoinThe serum concentration of Itraconazole can be decreased when it is combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Itraconazole.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Itraconazole.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Itraconazole.
PimozideItraconazole may increase the arrhythmogenic activities of Pimozide.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Itraconazole.
PinaveriumThe risk or severity of adverse effects can be increased when Itraconazole is combined with Pinaverium.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Itraconazole.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Itraconazole.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Itraconazole.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Itraconazole.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Itraconazole.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Itraconazole.
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Itraconazole.
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Itraconazole.
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Itraconazole resulting in a loss in efficacy.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Itraconazole.
PrazepamThe metabolism of Prazepam can be decreased when combined with Itraconazole.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Itraconazole.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Itraconazole.
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Itraconazole.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Itraconazole.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Itraconazole.
PregabalinThe risk or severity of adverse effects can be increased when Itraconazole is combined with Pregabalin.
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Itraconazole.
PrenylamineThe risk or severity of adverse effects can be increased when Itraconazole is combined with Prenylamine.
PrimaquineItraconazole may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe serum concentration of Itraconazole can be decreased when it is combined with Primidone.
ProcainamideItraconazole may increase the QTc-prolonging activities of Procainamide.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Itraconazole.
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Itraconazole.
ProguanilThe metabolism of Proguanil can be decreased when combined with Itraconazole.
PromazineItraconazole may increase the QTc-prolonging activities of Promazine.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Itraconazole.
PropofolThe metabolism of Propofol can be decreased when combined with Itraconazole.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Itraconazole.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Itraconazole.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Itraconazole.
QuazepamThe metabolism of Quazepam can be decreased when combined with Itraconazole.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Itraconazole.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Itraconazole.
QuinidineThe metabolism of Quinidine can be decreased when combined with Itraconazole.
QuinineThe serum concentration of Quinine can be increased when it is combined with Itraconazole.
RabeprazoleThe serum concentration of Itraconazole can be decreased when it is combined with Rabeprazole.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Itraconazole.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Itraconazole.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Itraconazole.
RanitidineThe serum concentration of Itraconazole can be decreased when it is combined with Ranitidine.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Itraconazole.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Itraconazole.
RanolazineThe metabolism of Itraconazole can be decreased when combined with Ranolazine.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Itraconazole.
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Itraconazole.
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Itraconazole.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Itraconazole.
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Itraconazole.
RifabutinThe serum concentration of Itraconazole can be decreased when it is combined with Rifabutin.
RifabutinThe metabolism of Rifabutin can be decreased when combined with Itraconazole.
RifampicinThe serum concentration of Itraconazole can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Itraconazole.
RifapentineThe serum concentration of Itraconazole can be decreased when it is combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Itraconazole.
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Itraconazole.
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Itraconazole.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Itraconazole.
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Itraconazole.
RisedronateThe risk or severity of adverse effects can be increased when Itraconazole is combined with Risedronate.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Itraconazole.
RitonavirThe serum concentration of Itraconazole can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Itraconazole.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Itraconazole.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Itraconazole.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Itraconazole.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Itraconazole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Itraconazole.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Itraconazole.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Itraconazole.
Roxatidine acetateThe serum concentration of Itraconazole can be decreased when it is combined with Roxatidine acetate.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Itraconazole.
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Itraconazole.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Itraconazole.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Itraconazole.
SaquinavirItraconazole may increase the QTc-prolonging activities of Saquinavir.
SaquinavirThe metabolism of Itraconazole can be decreased when combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Itraconazole.
SelegilineThe metabolism of Selegiline can be decreased when combined with Itraconazole.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Itraconazole.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Itraconazole.
SertindoleThe metabolism of Sertindole can be decreased when combined with Itraconazole.
SertralineThe metabolism of Sertraline can be decreased when combined with Itraconazole.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Itraconazole.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Itraconazole.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Itraconazole.
SildenafilThe metabolism of Itraconazole can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Itraconazole.
SiltuximabThe serum concentration of Itraconazole can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Itraconazole can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Itraconazole.
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Itraconazole.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Itraconazole.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Itraconazole.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Itraconazole.
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Itraconazole.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Itraconazole.
SotalolItraconazole may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Itraconazole.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Itraconazole.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Itraconazole.
St. John's WortThe serum concentration of Itraconazole can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Itraconazole can be increased when it is combined with Stiripentol.
SucralfateSucralfate can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Itraconazole.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Itraconazole.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Itraconazole.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Itraconazole.
SulfisoxazoleItraconazole may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Itraconazole can be decreased when combined with Sulfisoxazole.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Itraconazole.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Itraconazole.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Itraconazole.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Itraconazole.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Itraconazole.
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Itraconazole.
TAK-390MRThe serum concentration of Itraconazole can be decreased when it is combined with TAK-390MR.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Itraconazole.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Itraconazole.
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Itraconazole.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Itraconazole.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Itraconazole.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Itraconazole.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Itraconazole.
TelaprevirThe serum concentration of Itraconazole can be increased when it is combined with Telaprevir.
TelavancinItraconazole may increase the QTc-prolonging activities of Telavancin.
TelithromycinThe serum concentration of Telithromycin can be increased when it is combined with Itraconazole.
TelithromycinThe metabolism of Itraconazole can be decreased when combined with Telithromycin.
TemazepamThe metabolism of Temazepam can be decreased when combined with Itraconazole.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Itraconazole.
TeniposideThe metabolism of Teniposide can be decreased when combined with Itraconazole.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Itraconazole.
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Itraconazole.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Itraconazole.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Itraconazole.
TetrabenazineItraconazole may increase the QTc-prolonging activities of Tetrabenazine.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Itraconazole.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Itraconazole.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Itraconazole.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Itraconazole.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Itraconazole.
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Itraconazole resulting in a loss in efficacy.
TiclopidineThe metabolism of Itraconazole can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Itraconazole.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Itraconazole.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Itraconazole.
TipranavirThe serum concentration of Itraconazole can be increased when it is combined with Tipranavir.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Itraconazole.
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Itraconazole.
TocilizumabThe serum concentration of Itraconazole can be decreased when it is combined with Tocilizumab.
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Itraconazole.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Itraconazole is combined with Tolfenamic Acid.
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Itraconazole.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Itraconazole.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Itraconazole.
ToremifeneThe risk or severity of adverse effects can be increased when Itraconazole is combined with Toremifene.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Itraconazole.
TramadolThe serum concentration of Tramadol can be increased when it is combined with Itraconazole.
TranilastThe risk or severity of adverse effects can be increased when Itraconazole is combined with Tranilast.
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Itraconazole.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Itraconazole.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Itraconazole.
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Itraconazole.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Itraconazole.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Itraconazole.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Itraconazole.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Itraconazole.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Itraconazole.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Itraconazole.
UdenafilThe metabolism of Udenafil can be decreased when combined with Itraconazole.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Itraconazole.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Itraconazole.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Itraconazole.
VandetanibThe metabolism of Vandetanib can be decreased when combined with Itraconazole.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Itraconazole.
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Itraconazole.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Itraconazole.
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Itraconazole.
VenlafaxineThe metabolism of Itraconazole can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Itraconazole.
VerapamilThe metabolism of Itraconazole can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Itraconazole.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Itraconazole.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Itraconazole.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Itraconazole.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Itraconazole.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Itraconazole.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Itraconazole.
VinorelbineThe risk or severity of adverse effects can be increased when Itraconazole is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Itraconazole.
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Itraconazole.
VoriconazoleThe metabolism of Itraconazole can be decreased when combined with Voriconazole.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Itraconazole.
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Itraconazole.
XylometazolineThe risk or severity of adverse effects can be increased when Itraconazole is combined with Xylometazoline.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Itraconazole.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Itraconazole.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Itraconazole.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Itraconazole.
ZiconotideThe risk or severity of adverse effects can be increased when Itraconazole is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Itraconazole.
ZileutonThe metabolism of Zileuton can be decreased when combined with Itraconazole.
ZiprasidoneThe metabolism of Itraconazole can be decreased when combined with Ziprasidone.
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Itraconazole.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Itraconazole.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Itraconazole.
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Itraconazole.
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Itraconazole.
Food Interactions
  • Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
  • Avoid taking with grapefruit juice.
  • Take after a full meal.
  • Take with food.

Targets

Kind
Protein
Organism
Yeast
Pharmacological action
yes
Actions
inhibitor
General Function:
Sterol 14-demethylase activity
Specific Function:
Catalyzes C14-demethylation of lanosterol which is critical for ergosterol biosynthesis. It transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol (By similarity).
Gene Name:
ERG11
Uniprot ID:
P50859
Molecular Weight:
61304.95 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Gachotte D, Pierson CA, Lees ND, Barbuch R, Koegel C, Bard M: A yeast sterol auxotroph (erg25) is rescued by addition of azole antifungals and reduced levels of heme. Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11173-8. [PubMed:9326581 ]
  4. Henry KW, Nickels JT, Edlind TD: Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors. Antimicrob Agents Chemother. 2000 Oct;44(10):2693-700. [PubMed:10991846 ]
  5. Morales IJ, Vohra PK, Puri V, Kottom TJ, Limper AH, Thomas CF Jr: Characterization of a lanosterol 14 alpha-demethylase from Pneumocystis carinii. Am J Respir Cell Mol Biol. 2003 Aug;29(2):232-8. Epub 2003 Feb 26. [PubMed:12606318 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sterol 14-demethylase activity
Specific Function:
Catalyzes C14-demethylation of lanosterol; it transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol.
Gene Name:
CYP51A1
Uniprot ID:
Q16850
Molecular Weight:
56805.26 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Cotrim PC, Garrity LK, Beverley SM: Isolation of genes mediating resistance to inhibitors of nucleoside and ergosterol metabolism in Leishmania by overexpression/selection. J Biol Chem. 1999 Dec 31;274(53):37723-30. [PubMed:10608831 ]
  3. Carrillo-Munoz AJ, Giusiano G, Ezkurra PA, Quindos G: Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9. [PubMed:16964330 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Niwa T, Shiraga T, Takagi A: Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 2005 Sep;28(9):1805-8. [PubMed:16141567 ]
  2. Sakaeda T, Iwaki K, Kakumoto M, Nishikawa M, Niwa T, Jin JS, Nakamura T, Nishiguchi K, Okamura N, Okumura K: Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol. 2005 Jun;57(6):759-64. [PubMed:15969931 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Dresser GK, Spence JD, Bailey DG: Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000 Jan;38(1):41-57. [PubMed:10668858 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Walsky RL, Astuccio AV, Obach RS: Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol. 2006 Dec;46(12):1426-38. [PubMed:17101742 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
  2. Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW: Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother. 2002 Jan;46(1):160-5. [PubMed:11751127 ]
  3. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  4. Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K: Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull. 1999 Dec;22(12):1355-9. [PubMed:10746169 ]
  5. Masuda S, Inui K: [Molecular mechanisms on drug transporters in the drug absorption and disposition]. Nihon Rinsho. 2002 Jan;60(1):65-73. [PubMed:11808341 ]
  6. Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ: Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther. 2003 Mar;73(3):192-8. [PubMed:12621384 ]
  7. Sakaeda T, Iwaki K, Kakumoto M, Nishikawa M, Niwa T, Jin JS, Nakamura T, Nishiguchi K, Okamura N, Okumura K: Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol. 2005 Jun;57(6):759-64. [PubMed:15969931 ]
  8. Saito M, Hirata-Koizumi M, Miyake S, Hasegawa R: Comparison of information on the pharmacokinetic interactions of Ca antagonists in the package inserts from three countries (Japan, USA and UK). Eur J Clin Pharmacol. 2005 Aug;61(7):531-6. Epub 2005 Jul 23. [PubMed:16041596 ]
  9. Shon JH, Yoon YR, Hong WS, Nguyen PM, Lee SS, Choi YG, Cha IJ, Shin JG: Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther. 2005 Aug;78(2):191-201. [PubMed:16084853 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2016 02:16